Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Piper Sandler Maintains Overweight on InspireMD, Raises Price Target to $4.5

Author: Benzinga Newsdesk | November 02, 2023 03:58pm
Piper Sandler analyst Adam Maeder maintains InspireMD (NASDAQ:NSPR) with a Overweight and raises the price target from $3.5 to $4.5.

Posted In: NSPR

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist